SFM
RARE icon

Sphera Funds Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Sphera Funds Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-350,000
Closed -$8.05M – 113
2025
Q4 		$8.05M Buy
+350,000
New +$11.5M 1.56% 18
2025
Q3 		– Sell
-180,600
Closed -$6.57M – 131
2025
Q2 		$6.57M Buy
180,600
+130,600
+261% +$4.71M 1.54% 16
2025
Q1 		$1.81M Buy
+50,000
New +$2.08M 0.42% 74
2024
Q2 		– Sell
-55,000
Closed -$2.57M – 132
2024
Q1 		$2.57M Buy
+55,000
New +$2.59M 0.36% 68

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Sphera Funds Management's RARE Position: Q1 2026 in Review

Sphera Funds Management increased its Ultragenyx Pharmaceutical (RARE) stake by 169% in Q1 2026, buying an estimated $11.5M and bringing the position to 809,333 shares worth $17M. The position accounts for 2.69% of the portfolio, ranked #9.

Sphera Funds Management first reported a position in RARE in Q2 2015 and has held it in 19 quarters since. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Sphera Funds Management held 809,333 shares of Ultragenyx Pharmaceutical worth $17M as of Q1 2026.
  • Sphera Funds Management bought 508,710 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $11.5M.
  • Ultragenyx Pharmaceutical made up 2.69% of Sphera Funds Management's portfolio in Q1 2026, its #9 holding.
  • Sphera Funds Management first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and has held it in 19 quarters since.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.